A pair of properly fitting running shoes will feel better on your feet and help you run more comfortably than a pair of shoes that fit poorly or are worn past their expiration date, according to ...

With no hidden fees, easy app integrations and reimbursements for transactions at any ATM worldwide, Novo’s business checking account¹ has a lot to offer small business owners who value simplicity.

Novo Nordisk has experienced a 50% drop due to potential tariffs and recent clinical trial results but remains strong in diabetes treatment, insulin, and GLP-1 products. I outline the bull case ...

Danish drugmaker Novo Nordisk has been dethroned by German software giant SAP as Europe’s most valuable company. SAP has soared some 40 per cent over the last year as investors celebrated its ...

However, hope is on the horizon with Ionna, a new fast-charging network backed by major automakers, promising a seamless and dependable charging experience. Ionna is a collaborative effort funded by ...

Novo Nordisk on Saturday said its diabetes pill Rybelsus showed cardiovascular benefits in a late-stage trial, paving the way for it to become a new treatment option for people living with ...

But I am pleased to say there is hope, for I have visited an Ionna charger, and it's everything that chargers should have been from the start. Ionna is funded by eight automakers: BMW, General Motors, ...

Shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) climbed ~95% in the premarket trading on Friday after the Texas-based biotech announced an exclusive license agreement with Novo Nordisk (NVO ...

Danish pharmaceutical company Novo Nordisk — best known for its blockbuster weight-loss drugs Ozempic and Wegovy — has signed a $2 billion deal to acquire the global rights to an experimental ...

But I am pleased to say there is hope, for I have visited an Ionna charger, and it's everything that chargers should have been from the start. Ionna is funded by eight automakers: BMW, General ...

Credit: Cunaplus_M.Faba via Getty Images. Novo Nordisk has signed a deal worth up to $1bn with Lexicon Pharmaceuticals for the exclusive global rights to LX9851, an experimental oral treatment for ...